RESTORE Act of 2019
USA116th CongressHR-4563| House
| Updated: 10/28/2019
Brian K. Fitzpatrick
Republican Representative
Pennsylvania
Cosponsors (5)
Crime and Federal Government Surveillance Subcommittee, Health Subcommittee, Judiciary Committee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Restoring Enforcement Standards to Track Opioids Responsively and Effectively Act of 2019 or the RESTORE Act of 2019 This bill repeals the Ensuring Patient Access and Effective Drug Enforcement Act of 2016. That act modified the standards that the Drug Enforcement Administration must apply when deciding whether to deny, revoke, or suspend the registration of a manufacturer, distributor, or dispenser of controlled substances (i.e., substances regulated under federal law based on their medical use and potential for dependence and abuse).
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
Crime and Law Enforcement
Administrative remediesCongressional oversightCrime preventionCriminal investigation, prosecution, interrogationDepartment of JusticeDrug trafficking and controlled substancesFraud offenses and financial crimesHealth care coverage and accessLicensing and registrationsMedical educationPrescription drugsRetail and wholesale trades
RESTORE Act of 2019
USA116th CongressHR-4563| House
| Updated: 10/28/2019
Restoring Enforcement Standards to Track Opioids Responsively and Effectively Act of 2019 or the RESTORE Act of 2019 This bill repeals the Ensuring Patient Access and Effective Drug Enforcement Act of 2016. That act modified the standards that the Drug Enforcement Administration must apply when deciding whether to deny, revoke, or suspend the registration of a manufacturer, distributor, or dispenser of controlled substances (i.e., substances regulated under federal law based on their medical use and potential for dependence and abuse).
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
Brian K. Fitzpatrick
Republican Representative
Pennsylvania
Cosponsors (5)
Crime and Federal Government Surveillance Subcommittee, Health Subcommittee, Judiciary Committee, Energy and Commerce Committee
Crime and Law Enforcement
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Administrative remediesCongressional oversightCrime preventionCriminal investigation, prosecution, interrogationDepartment of JusticeDrug trafficking and controlled substancesFraud offenses and financial crimesHealth care coverage and accessLicensing and registrationsMedical educationPrescription drugsRetail and wholesale trades